<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01590888</url>
  </required_header>
  <id_info>
    <org_study_id>PBT2-203</org_study_id>
    <nct_id>NCT01590888</nct_id>
  </id_info>
  <brief_title>Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease</brief_title>
  <acronym>Reach2HD</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prana Biotechnology Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prana Biotechnology Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Huntington disease (HD) is an inherited neurodegenerative disease which affects over 30,000
      people in both the United States and Australia. HD is characterized by brain cell death that
      usually begins between the ages of 30 to 50, and results in motor, cognitive and behavioral
      signs and symptoms. While there are medications to help relieve some of the disease symptoms,
      there is no known treatment to address the cognitive impairment associated with HD.

      Normally occurring metals in the brain play a significant role in diseases such as Alzheimer
      disease and HD. PBT2 is a drug designed to interrupt interactions between these biological
      metals and target proteins in the brain, to prevent deterioration of brain cells. PBT2, has
      shown in animal models, and as well as in a small group of patients with Alzheimer's disease,
      it may improve cognition. There is some indication in animal models of HD, that the drug may
      improve motor function and control and reduce the amount of brain cell degeneration.

      PBT2-203 will evaluate how safe and well tolerated PBT2 is at a dose of 100 mg or 250 mg a
      day administered as oral daily capsules compared to a placebo over a six month treatment
      period. The trial will also measure whether there is an effect on cognitive abilities as well
      as other HD symptoms including motor and overall functioning of individuals with HD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of PBT2 in Patients With HD</measure>
    <time_frame>Baseline to 26 weeks</time_frame>
    <description>As measured by the total number of participants in each dose group who reported at least one adverse events during the study,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cognitive Test Battery - Composite z Scores</measure>
    <time_frame>Baseline to 26 weeks</time_frame>
    <description>Cognition composite z-scores were calculated for each participant. The composite scores were defined as the mean of the individual z-scores for the various cognition assessments. The Main Composite z-score was calculated for Category Fluency Test, Trail Making Test Part B, Map Search, Symbol Digit Modalities Test and Stroop Word Reading Test. The Exploratory Composite z-score was calculated for Category Fluency Test, Trail Making Test Part B, Map Search, Symbol Digit Modalities Test, Stroop Word Reading Test and Speeded Tapping test. The Executive Function Composite z-score was calculated from Category Fluency Test and Trail Making Test Part B. There is no unit of measure for the z score as it is the pure number calculated from the SD from the mean. A higher z score indicates an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Motor Function</measure>
    <time_frame>Baseline to 26 weeks</time_frame>
    <description>Total motor score calculated from the Unified Huntington Disease Rating Scale - Motor Function. The motor section of the UHDRS assesses motor features of HD with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. The total motor impairment scores is the sum of all the individual motor ratings, with higher scores indicating more severe motor impairment than lower scores. A maximum score of 60 is possible (range 0-60).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Functional Abilities</measure>
    <time_frame>Baseline to 26 weeks</time_frame>
    <description>Total Functional Capacity (TFC) assessment was based on an individual's ability to perform common daily tasks. TFC score range was 0 to 13.
Higher scores on the function scales indicate better functioning than lower scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Behaviour</measure>
    <time_frame>Baseline to 26 weeks</time_frame>
    <description>Total Behavioural score from the Unified Huntington Disease Rating Scale. The behavioural assessment measures the frequency and severity of symptoms related to affect, thought content and coping styles. The total behaviour score is the sum of all responses, with scale range of 0 to 8. Higher scores on the behaviour assessments indicate more severe disturbance than lower scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Investigator Global Assessments by Efficacy Index</measure>
    <time_frame>Baseline to 26 weeks</time_frame>
    <description>Global function was assessed by the Investigator using the clinical global impression (CGI) scale which included assessing the severity of illness and global improvement and calculating the efficacy index for each participant. The efficacy index aims to relate therapeutic effects to reported side effects as assessed by the Investigator (range from 0 [marked improvement and no side effects] to 4 [unchanged or worse] and side effects outweigh therapeutic effects) and is calculated for each participant by dividing the therapeutic effect score by the side effects score. An improvement is reflected by CGI scale Efficacy Index values &gt;1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Biomarkers</measure>
    <time_frame>Baseline to 26 weeks</time_frame>
    <description>Biomarkers assessed primarily with mutant huntingtin protein, normalised to lysate protein concentrations, as a change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Brain Function (MRI)</measure>
    <time_frame>Baseline to 26 weeks</time_frame>
    <description>Measure of whole brain iron concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Biomarkers</measure>
    <time_frame>Baseline to 26 weeks</time_frame>
    <description>Biomarkers assessed primarily with soluble huntingtin protein, normalised to lysate protein concentrations, as a change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Biomarkers - Selenium</measure>
    <time_frame>Baseline to 26 weeks</time_frame>
    <description>Biomarkers assessed primarily with plasma selenium as a change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urine Biomarkers</measure>
    <time_frame>Baseline to 26 weeks</time_frame>
    <description>Biomarkers assessed primarily with 8-hydroxy-2'-deoxyguanosine, normalised to creatinine concentrations, as a change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Brain Function (MRI)</measure>
    <time_frame>Baseline to 26 weeks</time_frame>
    <description>Measure of the structural brain volume as assessed by the left caudate volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cognitive Test Battery - TMT Part B</measure>
    <time_frame>Baseline to 26 weeks</time_frame>
    <description>Trail Making Test Part B was assessed by the number of seconds to complete the test (from 0 to 240 seconds).
The Trails Making Test Part B actual change from baseline at Week 26 was analysed.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Huntington Disease</condition>
  <arm_group>
    <arm_group_label>PBT2 250mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PBT2 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PBT2</intervention_name>
    <description>250mg capsules administered orally once per day for 26 weeks</description>
    <arm_group_label>PBT2 250mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PBT2</intervention_name>
    <description>100mg capsules administered orally once per day for 26 weeks</description>
    <arm_group_label>PBT2 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching capsules administered orally once per day for 26 weeks</description>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who:

               1. Provide signed informed consent in accordance with local regulations.

               2. Have Huntington disease including clinical features of HD and a CAG repeat number
                  ≥ 36.

               3. Have a Total Functional Capacity between 6 and 13, inclusive.

               4. Have cognitive impairment as demonstrated by a MoCA score of ≥ 12.

               5. Are ≥ 25 years of age.

               6. If taking tetrabenazine, have been on a stable dose for at least 3 months.

               7. If female, are either a) of childbearing potential and compliant in using
                  adequate birth control or b) not of childbearing potential.

               8. If male, is either a) of reproductive potential and compliant in using adequate
                  birth control or b) not of reproductive potential.

               9. Have a study partner who is willing to provide consent and spends on average at
                  least two hours a day for at least four days a week with the patient, is fluent
                  in the English language, and who agrees to attend certain study visits and
                  provide accurate information about the patient.

              10. Are able to swallow oral capsules.

              11. Are fluent in the English language for the administration of rating scales and
                  have sufficient visual, hearing and motor skills to complete procedures.

                  Exclusion Criteria:

          -  Patients who:

               1. Have an allergy to PBT2 or its excipients.

               2. Have other known primary neurodegenerative disorders associated with dementia.

               3. Have known dementia syndromes due to non-primary CNS disease.

               4. Have another condition that in the investigator's judgment is resulting in
                  clinically significant cognitive impairment.

               5. In the opinion of the investigator, have any clinically significant uncontrolled
                  medical or psychiatric illness, including history of seizures.

               6. Have clinically significant cardiovascular, hepatic, renal, pulmonary, metabolic
                  or endocrine disease that, in the opinion of the investigator, would interfere
                  with an individual's participation in the study.

               7. Have a calculated creatinine clearance at Screening of &lt;50mL/min.

               8. Have a history of malignancy diagnosed within 2 years of Screening.

               9. Are pregnant or lactating females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ray Dorsey</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Neurological Institute</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital East</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Struthers Parkinson's Center</name>
      <address>
        <city>Golden Valley</city>
        <state>Minnesota</state>
        <zip>55427</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Health Science Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Booth Gardner Parkinson's Care Center</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calvary Health Care Bethlehem</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3800</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Melbourne Normanby Unit - St Vincents/St Georges</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurodegenerative Disorders Research</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW; PBT2-201-EURO study group. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2008 Sep;7(9):779-86. doi: 10.1016/S1474-4422(08)70167-4. Epub 2008 Jul 30. Erratum in: Lancet Neurol. 2009 Nov;8(11):981.</citation>
    <PMID>18672400</PMID>
  </reference>
  <reference>
    <citation>Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, Harrison J, Lannfelt L, Blennow K, Zetterberg H, Ingelsson M, Masters CL, Tanzi RE, Cummings JL, Herd CM, Bush AI. PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis. 2010;20(2):509-16. doi: 10.3233/JAD-2010-1390.</citation>
    <PMID>20164561</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2012</study_first_submitted>
  <study_first_submitted_qc>May 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2012</study_first_posted>
  <results_first_submitted>November 17, 2015</results_first_submitted>
  <results_first_submitted_qc>June 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 18, 2016</results_first_posted>
  <last_update_submitted>June 7, 2016</last_update_submitted>
  <last_update_submitted_qc>June 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Twenty sites were initiated for the study, with participants enrolled at 14 sites in the US and 5 sites in Australia.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>PBT2 250mg</title>
          <description>PBT2: 250mg capsules administered orally once per day for 26 weeks</description>
        </group>
        <group group_id="P2">
          <title>PBT2 100mg</title>
          <description>PBT2: 100mg capsules administered orally once per day for 26 weeks</description>
        </group>
        <group group_id="P3">
          <title>Sugar Pill</title>
          <description>Placebo: Matching capsules administered orally once per day for 26 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PBT2 250mg</title>
          <description>PBT2: 250mg capsules administered orally once per day for 26 weeks</description>
        </group>
        <group group_id="B2">
          <title>PBT2 100mg</title>
          <description>PBT2: 100mg capsules administered orally once per day for 26 weeks</description>
        </group>
        <group group_id="B3">
          <title>Sugar Pill</title>
          <description>Placebo: Matching capsules administered orally once per day for 26 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="35"/>
            <count group_id="B4" value="109"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.3" spread="10.4"/>
                    <measurement group_id="B2" value="54.1" spread="12.1"/>
                    <measurement group_id="B3" value="51.2" spread="10.4"/>
                    <measurement group_id="B4" value="51.9" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.51" spread="4.89"/>
                    <measurement group_id="B2" value="25.40" spread="4.53"/>
                    <measurement group_id="B3" value="27.09" spread="6.03"/>
                    <measurement group_id="B4" value="25.98" spread="5.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Function Capacity</title>
          <description>Total function capacity (TFC) is a scale measuring the participants capacity to perform 5 areas - their capacity to work, capacity to handle financial affairs, capacity to manage domestic responsibilities, capacity to perform activities of daily living and level of care required (home or care facility). The scale used is a TOTAL of each of the 5 areas, which range from 0 (unable to perform or require full care) to either 2 or 3 (normal, no assistance required). The TFC can scored from 0 to 13. The lower the score, the more severe the disease state of Huntington disease is.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.1" spread="2.2"/>
                    <measurement group_id="B2" value="9.3" spread="2.3"/>
                    <measurement group_id="B3" value="9.3" spread="1.6"/>
                    <measurement group_id="B4" value="9.2" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CAG Larger Allele Repeat Length</title>
          <description>Huntington disease (HD) is a dominant genetic disorder. Mutations in the HTT gene cause HD. The HTT mutation involves a DNA segment known as a Cytosine, Adenine and Guanine (CAG) trinucleotide repeat, a series of three DNA building blocks. Normally, the CAG segment is repeated 10 to 35 times within the gene. In people with HD, the CAG segment is repeated more than 36 times with higher repeat numbers normally indicating earlier onset of the disease and increased severity of symptoms.</description>
          <units>CAG repeats</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.4" spread="4.6"/>
                    <measurement group_id="B2" value="43.2" spread="2.8"/>
                    <measurement group_id="B3" value="44.1" spread="3.9"/>
                    <measurement group_id="B4" value="43.9" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CAG Smaller Allele Repeat Length</title>
          <description>Huntington disease (HD) is a dominant genetic disorder. Mutations in the HTT gene cause HD. The HTT mutation involves a DNA segment known as a Cytosine, Adenine and Guanine (CAG) trinucleotide repeat, a series of three DNA building blocks. Normally, the CAG segment is repeated 10 to 35 times within the gene. In people with HD, the CAG segment is repeated more than 36 times with higher repeat numbers normally indicating earlier onset of the disease and increased severity of symptoms.
HD is a dominant genetic disorder.</description>
          <units>CAG repeats</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.8" spread="4.4"/>
                    <measurement group_id="B2" value="18.5" spread="3.0"/>
                    <measurement group_id="B3" value="20.0" spread="4.8"/>
                    <measurement group_id="B4" value="19.1" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Burden</title>
          <description>Disease burden in patients with Huntington disease is calculated by (CAG repeat length - 35) x Age at Baseline, with the higher score indicating a greater Disease Burden for a patient.</description>
          <units>CAG repeats*years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="411.68" spread="104.96"/>
                    <measurement group_id="B2" value="392.54" spread="96.10"/>
                    <measurement group_id="B3" value="410.07" spread="110.02"/>
                    <measurement group_id="B4" value="404.49" spread="103.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of PBT2 in Patients With HD</title>
        <description>As measured by the total number of participants in each dose group who reported at least one adverse events during the study,</description>
        <time_frame>Baseline to 26 weeks</time_frame>
        <population>Safety population as defined as all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>PBT2 250mg</title>
            <description>PBT2: 250mg capsules administered orally once per day for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>PBT2 100mg</title>
            <description>PBT2: 100mg capsules administered orally once per day for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sugar Pill</title>
            <description>Placebo: Matching capsules administered orally once per day for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of PBT2 in Patients With HD</title>
          <description>As measured by the total number of participants in each dose group who reported at least one adverse events during the study,</description>
          <population>Safety population as defined as all participants who received at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cognitive Test Battery - Composite z Scores</title>
        <description>Cognition composite z-scores were calculated for each participant. The composite scores were defined as the mean of the individual z-scores for the various cognition assessments. The Main Composite z-score was calculated for Category Fluency Test, Trail Making Test Part B, Map Search, Symbol Digit Modalities Test and Stroop Word Reading Test. The Exploratory Composite z-score was calculated for Category Fluency Test, Trail Making Test Part B, Map Search, Symbol Digit Modalities Test, Stroop Word Reading Test and Speeded Tapping test. The Executive Function Composite z-score was calculated from Category Fluency Test and Trail Making Test Part B. There is no unit of measure for the z score as it is the pure number calculated from the SD from the mean. A higher z score indicates an improvement.</description>
        <time_frame>Baseline to 26 weeks</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>PBT2 250mg</title>
            <description>PBT2: 250mg capsules administered orally once per day for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>PBT2 100mg</title>
            <description>PBT2: 100mg capsules administered orally once per day for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sugar Pill</title>
            <description>Placebo: Matching capsules administered orally once per day for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cognitive Test Battery - Composite z Scores</title>
          <description>Cognition composite z-scores were calculated for each participant. The composite scores were defined as the mean of the individual z-scores for the various cognition assessments. The Main Composite z-score was calculated for Category Fluency Test, Trail Making Test Part B, Map Search, Symbol Digit Modalities Test and Stroop Word Reading Test. The Exploratory Composite z-score was calculated for Category Fluency Test, Trail Making Test Part B, Map Search, Symbol Digit Modalities Test, Stroop Word Reading Test and Speeded Tapping test. The Executive Function Composite z-score was calculated from Category Fluency Test and Trail Making Test Part B. There is no unit of measure for the z score as it is the pure number calculated from the SD from the mean. A higher z score indicates an improvement.</description>
          <population>Intent to Treat</population>
          <units>z score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Main Composite z-score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0592" spread="0.2670"/>
                    <measurement group_id="O2" value="-0.0413" spread="0.3170"/>
                    <measurement group_id="O3" value="-0.0194" spread="0.2374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exploratory Composite z-score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0530" spread="0.2568"/>
                    <measurement group_id="O2" value="-0.0287" spread="0.3349"/>
                    <measurement group_id="O3" value="-0.0144" spread="0.2331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Executive Function z-score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2274" spread="0.4288"/>
                    <measurement group_id="O2" value="-0.1026" spread="0.4771"/>
                    <measurement group_id="O3" value="0.0553" spread="0.3385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Motor Function</title>
        <description>Total motor score calculated from the Unified Huntington Disease Rating Scale - Motor Function. The motor section of the UHDRS assesses motor features of HD with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. The total motor impairment scores is the sum of all the individual motor ratings, with higher scores indicating more severe motor impairment than lower scores. A maximum score of 60 is possible (range 0-60).</description>
        <time_frame>Baseline to 26 weeks</time_frame>
        <population>Intent to Treat population analysed, and defined as all participants who received at least one dose of study and underwent at least one post baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>PBT2 250mg</title>
            <description>PBT2: 250mg capsules administered orally once per day for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>PBT2 100mg</title>
            <description>PBT2: 100mg capsules administered orally once per day for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sugar Pill</title>
            <description>Placebo: Matching capsules administered orally once per day for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Motor Function</title>
          <description>Total motor score calculated from the Unified Huntington Disease Rating Scale - Motor Function. The motor section of the UHDRS assesses motor features of HD with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. The total motor impairment scores is the sum of all the individual motor ratings, with higher scores indicating more severe motor impairment than lower scores. A maximum score of 60 is possible (range 0-60).</description>
          <population>Intent to Treat population analysed, and defined as all participants who received at least one dose of study and underwent at least one post baseline efficacy assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="7.6"/>
                    <measurement group_id="O2" value="1.3" spread="9.0"/>
                    <measurement group_id="O3" value="-1.3" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Functional Abilities</title>
        <description>Total Functional Capacity (TFC) assessment was based on an individual's ability to perform common daily tasks. TFC score range was 0 to 13.
Higher scores on the function scales indicate better functioning than lower scores.</description>
        <time_frame>Baseline to 26 weeks</time_frame>
        <population>Intent to Treat Population analysed</population>
        <group_list>
          <group group_id="O1">
            <title>PBT2 250mg</title>
            <description>PBT2: 250mg capsules administered orally once per day for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>PBT2 100mg</title>
            <description>PBT2: 100mg capsules administered orally once per day for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sugar Pill</title>
            <description>Placebo: Matching capsules administered orally once per day for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Functional Abilities</title>
          <description>Total Functional Capacity (TFC) assessment was based on an individual's ability to perform common daily tasks. TFC score range was 0 to 13.
Higher scores on the function scales indicate better functioning than lower scores.</description>
          <population>Intent to Treat Population analysed</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.0"/>
                    <measurement group_id="O2" value="1.3" spread="1.0"/>
                    <measurement group_id="O3" value="1.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Behaviour</title>
        <description>Total Behavioural score from the Unified Huntington Disease Rating Scale. The behavioural assessment measures the frequency and severity of symptoms related to affect, thought content and coping styles. The total behaviour score is the sum of all responses, with scale range of 0 to 8. Higher scores on the behaviour assessments indicate more severe disturbance than lower scores.</description>
        <time_frame>Baseline to 26 weeks</time_frame>
        <population>Intent to Treat population analysed</population>
        <group_list>
          <group group_id="O1">
            <title>PBT2 250mg</title>
            <description>PBT2: 250mg capsules administered orally once per day for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>PBT2 100mg</title>
            <description>PBT2: 100mg capsules administered orally once per day for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sugar Pill</title>
            <description>Placebo: Matching capsules administered orally once per day for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Behaviour</title>
          <description>Total Behavioural score from the Unified Huntington Disease Rating Scale. The behavioural assessment measures the frequency and severity of symptoms related to affect, thought content and coping styles. The total behaviour score is the sum of all responses, with scale range of 0 to 8. Higher scores on the behaviour assessments indicate more severe disturbance than lower scores.</description>
          <population>Intent to Treat population analysed</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="9.2"/>
                    <measurement group_id="O2" value="3.0" spread="15.9"/>
                    <measurement group_id="O3" value="0.7" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Investigator Global Assessments by Efficacy Index</title>
        <description>Global function was assessed by the Investigator using the clinical global impression (CGI) scale which included assessing the severity of illness and global improvement and calculating the efficacy index for each participant. The efficacy index aims to relate therapeutic effects to reported side effects as assessed by the Investigator (range from 0 [marked improvement and no side effects] to 4 [unchanged or worse] and side effects outweigh therapeutic effects) and is calculated for each participant by dividing the therapeutic effect score by the side effects score. An improvement is reflected by CGI scale Efficacy Index values &gt;1.</description>
        <time_frame>Baseline to 26 weeks</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>PBT2 250mg</title>
            <description>PBT2: 250mg capsules administered orally once per day for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>PBT2 100mg</title>
            <description>PBT2: 100mg capsules administered orally once per day for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sugar Pill</title>
            <description>Placebo: Matching capsules administered orally once per day for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Investigator Global Assessments by Efficacy Index</title>
          <description>Global function was assessed by the Investigator using the clinical global impression (CGI) scale which included assessing the severity of illness and global improvement and calculating the efficacy index for each participant. The efficacy index aims to relate therapeutic effects to reported side effects as assessed by the Investigator (range from 0 [marked improvement and no side effects] to 4 [unchanged or worse] and side effects outweigh therapeutic effects) and is calculated for each participant by dividing the therapeutic effect score by the side effects score. An improvement is reflected by CGI scale Efficacy Index values &gt;1.</description>
          <population>Intent to Treat</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.313" spread="0.592"/>
                    <measurement group_id="O2" value="1.276" spread="0.654"/>
                    <measurement group_id="O3" value="1.176" spread="0.459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Biomarkers</title>
        <description>Biomarkers assessed primarily with mutant huntingtin protein, normalised to lysate protein concentrations, as a change from baseline.</description>
        <time_frame>Baseline to 26 weeks</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>PBT2 250mg</title>
            <description>PBT2: 250mg capsules administered orally once per day for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>PBT2 100mg</title>
            <description>PBT2: 100mg capsules administered orally once per day for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sugar Pill</title>
            <description>Placebo: Matching capsules administered orally once per day for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Biomarkers</title>
          <description>Biomarkers assessed primarily with mutant huntingtin protein, normalised to lysate protein concentrations, as a change from baseline.</description>
          <population>ITT population</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" spread="24.39"/>
                    <measurement group_id="O2" value="0.14" spread="4.70"/>
                    <measurement group_id="O3" value="-1.72" spread="9.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Brain Function (MRI)</title>
        <description>Measure of whole brain iron concentrations.</description>
        <time_frame>Baseline to 26 weeks</time_frame>
        <population>ITT population. MRI was performed at one site only, resulting in a subset of participants available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PBT2 250mg</title>
            <description>PBT2: 250mg capsules administered orally once per day for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>PBT2 100mg</title>
            <description>PBT2: 100mg capsules administered orally once per day for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sugar Pill</title>
            <description>Placebo: Matching capsules administered orally once per day for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Brain Function (MRI)</title>
          <description>Measure of whole brain iron concentrations.</description>
          <population>ITT population. MRI was performed at one site only, resulting in a subset of participants available for analysis.</population>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0029" spread="0.0043"/>
                    <measurement group_id="O2" value="0.0067">Not applicable with an n equalling 1.</measurement>
                    <measurement group_id="O3" value="0.0098" spread="0.0115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Biomarkers</title>
        <description>Biomarkers assessed primarily with soluble huntingtin protein, normalised to lysate protein concentrations, as a change from baseline.</description>
        <time_frame>Baseline to 26 weeks</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>PBT2 250mg</title>
            <description>PBT2: 250mg capsules administered orally once per day for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>PBT2 100mg</title>
            <description>PBT2: 100mg capsules administered orally once per day for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sugar Pill</title>
            <description>Placebo: Matching capsules administered orally once per day for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Biomarkers</title>
          <description>Biomarkers assessed primarily with soluble huntingtin protein, normalised to lysate protein concentrations, as a change from baseline.</description>
          <population>ITT population</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.18" spread="8.23"/>
                    <measurement group_id="O2" value="-2.09" spread="5.44"/>
                    <measurement group_id="O3" value="-3.07" spread="5.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Biomarkers - Selenium</title>
        <description>Biomarkers assessed primarily with plasma selenium as a change from baseline.</description>
        <time_frame>Baseline to 26 weeks</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>PBT2 250mg</title>
            <description>PBT2: 250mg capsules administered orally once per day for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>PBT2 100mg</title>
            <description>PBT2: 100mg capsules administered orally once per day for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sugar Pill</title>
            <description>Placebo: Matching capsules administered orally once per day for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Biomarkers - Selenium</title>
          <description>Biomarkers assessed primarily with plasma selenium as a change from baseline.</description>
          <population>ITT population</population>
          <units>ug/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="28.1"/>
                    <measurement group_id="O2" value="-6.3" spread="18.2"/>
                    <measurement group_id="O3" value="2.0" spread="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urine Biomarkers</title>
        <description>Biomarkers assessed primarily with 8-hydroxy-2'-deoxyguanosine, normalised to creatinine concentrations, as a change from baseline.</description>
        <time_frame>Baseline to 26 weeks</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>PBT2 250mg</title>
            <description>PBT2: 250mg capsules administered orally once per day for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>PBT2 100mg</title>
            <description>PBT2: 100mg capsules administered orally once per day for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sugar Pill</title>
            <description>Placebo: Matching capsules administered orally once per day for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urine Biomarkers</title>
          <description>Biomarkers assessed primarily with 8-hydroxy-2'-deoxyguanosine, normalised to creatinine concentrations, as a change from baseline.</description>
          <population>ITT population</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4258" spread="1.3383"/>
                    <measurement group_id="O2" value="0.0832" spread="2.0456"/>
                    <measurement group_id="O3" value="35.5302" spread="208.5614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Brain Function (MRI)</title>
        <description>Measure of the structural brain volume as assessed by the left caudate volume.</description>
        <time_frame>Baseline to 26 weeks</time_frame>
        <population>ITT population. MRI was performed at one site only, resulting in a subset of participants available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PBT2 250mg</title>
            <description>PBT2: 250mg capsules administered orally once per day for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>PBT2 100mg</title>
            <description>PBT2: 100mg capsules administered orally once per day for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sugar Pill</title>
            <description>Placebo: Matching capsules administered orally once per day for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Brain Function (MRI)</title>
          <description>Measure of the structural brain volume as assessed by the left caudate volume.</description>
          <population>ITT population. MRI was performed at one site only, resulting in a subset of participants available for analysis.</population>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" spread="70.7"/>
                    <measurement group_id="O2" value="27.5" spread="94.0"/>
                    <measurement group_id="O3" value="-170.5" spread="67.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cognitive Test Battery - TMT Part B</title>
        <description>Trail Making Test Part B was assessed by the number of seconds to complete the test (from 0 to 240 seconds).
The Trails Making Test Part B actual change from baseline at Week 26 was analysed.</description>
        <time_frame>Baseline to 26 weeks</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>PBT2 250mg</title>
            <description>PBT2: 250mg capsules administered orally once per day for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>PBT2 100mg</title>
            <description>PBT2: 100mg capsules administered orally once per day for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sugar Pill</title>
            <description>Placebo: Matching capsules administered orally once per day for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cognitive Test Battery - TMT Part B</title>
          <description>Trail Making Test Part B was assessed by the number of seconds to complete the test (from 0 to 240 seconds).
The Trails Making Test Part B actual change from baseline at Week 26 was analysed.</description>
          <population>Intent to Treat</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" spread="30.0"/>
                    <measurement group_id="O2" value="12.8" spread="43.3"/>
                    <measurement group_id="O3" value="8.9" spread="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Reported AEs from time of consent to end of study (Week 30 or 4 weeks post cessation of study drug).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PBT2 250mg</title>
          <description>PBT2: 250mg capsules administered orally once per day for 26 weeks</description>
        </group>
        <group group_id="E2">
          <title>PBT2 100mg</title>
          <description>PBT2: 100mg capsules administered orally once per day for 26 weeks</description>
        </group>
        <group group_id="E3">
          <title>Sugar Pill</title>
          <description>Placebo: Matching capsules administered orally once per day for 26 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening of Huntington Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Stabilisation of Huntington Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychotic Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Huntington disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Muscolskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Caroline Herd</name_or_title>
      <organization>Prana Biotechnology</organization>
      <phone>+61393494906</phone>
      <email>info@pranabio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

